PDF下载 ( 1951 KB)
Effect of statins on hepatocellular carcinoma in patients with type 2 diabetes
-
摘要:
<正>肝细胞癌（HCC）为全球性疾病,其发病率在全球范围内各不相同,在北美（4. 9/100 000）和欧洲（5. 8/100 000）最低,在东亚地区（35. 5/100 000）最高,主要是因为东亚地区感染慢性乙型肝炎患者较多[1]。其致病因素包括慢性乙型肝炎或丙型肝炎、肝硬化、重度饮酒、遗传性血色素沉着症、黄曲霉毒素暴露、种族/基因组成、自身免疫性肝炎、非酒精性脂肪肝等[2-3]。其中有研究[4]发现,2型糖尿病会增加HCC的发病率,且Wang等[5]前瞻性研究表明与非糖尿病人群相比,糖尿病患者中包含
-
[1]BOSCH FX, RIBES J, DIAZ M, et al.Primary liver cancer:worldwide incidence and trends[J].Gastroenterology, 2004, 127:s5-s16. [2]BOSETTI C, TURATI F, LA-VECCHIA C.Hepatocellular carcinoma epidemiology[J].Best Pract Res Clin Gastroenterol, 2014, 28 (5) :753-770. [3]CUI YX, KONG F, ZHAO X, et al.Expression of O-GlcNAc transferase in hepatocellular carcinoma tissue and its clinical significance[J].J Jilin Univ:Med Edit, 2017, 43 (5) :980-984. (in Chinese) 崔银星, 孔菲, 赵旭, 等.O-GlcNAc转移酶在肝细胞癌组织中的表达及其临床意义[J].吉林大学学报:医学版, 2017, 43 (5) :980-984. [4]RAFT EJ, KAKATI D, BLOOMER JR, et al.Diabetes mellitus predicts occurrence of cirrhosis and hepatocellular cancer in alcoholic liver and non-alcoholic fatty liver diseases[J].J Clin Transl Hepatol, 2015, 3 (1) :9-16. [5]WANG P, KANG D, CAO W, et al.Diabetes mellitus and risk of hepatocellular carcinoma:A systematic review and Meta-analysis[J].Diabetes Metab Res Rev, 2012, 28 (2) :109-122. [6]LIU GP, ZHANG GL.Research progress on strategies for the treatment of hyperlipidemia in the elderly[J].China Med Herald, 2017, 14 (15) :55-58. (in Chinese) 刘桂萍, 张国领.老年人群高脂血症的治疗策略研究进展[J].中国医药导报, 2017, 14 (15) :55-58. [7]MICALLEF D, MICALLEF S, SCHEMBRIWISMAVER P, et al.Novel applications of COX-2 inhibitors, metformin, and statins for the primary chemoprevention of breast cancer[J].JTurk Ger Gynecol Assoc, 2016, 17 (4) :214-223. [8]ARCHIBUGI L, PICIUCCHI M, STIGLIANO S, et al.Exclusive and combined use of statins and aspirin and the risk of pancreatic cancer:A case-control study[J].Sci Rep, 2017, 7 (1) :13024. [9]KIM G, JANG SY, HAN E, et al.Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes:A nationwide nested case-control study[J].Int J Cancer, 2017, 140 (4) :798-806. [10]AZOULAY L, YIN H, FILION KB, et al.The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes:Nested case-control study[J].BMJ, 2012, 344:e3645. [11]ELSERAG HB, JOHNSON ML, HACHEM C, et al.Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes[J].Gastroenterology, 2009, 136 (5) :1601-1608. [12]FERLAY J, SHIN HR, BRAY F, et al.Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008[J].Int J Cancer, 2010, 127 (12) :2893-2917. [13]ZHAO RR, DENG YD, YUAN H.Epidemiological and clinical features of primary liver cancer:An analysis of 236 patients[J].J Clin Hepatol, 2016, 32 (8) :1538-1542. (in Chinese) 赵荣荣, 邓永东, 袁宏.236例原发性肝癌患者流行病学及临床特点分析[J].临床肝胆病杂志, 2016, 32 (8) :1538-1542. [14]LEE MY, LIN KD, HSIAO PJ, et al.The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipidemia, and gout in Taiwanese patients[J].Metabolism, 2012, 61 (2) :242-249. [15]DANKNER R, BOFFETTA P, BALICER RD, et al.Time-dependent risk of cancer after a diabetes diagnosis in a cohort of2.3 million adults[J].Am J Epidemiol, 2016, 183 (12) :1098-1106. [16]WANG ZS, HOU AM.Analysis on the risk factors of primary hepatic cancer related to viral infections[J].Int J Virol, 2015, 22 (6) :399-402. (in Chinese) 王智珊, 侯安明.病毒感染相关性原发性肝癌患病危险因素分析[J].国际病毒学杂志, 2015, 22 (6) :399-402. [17]WILD SH, MORLING JR, McALLISTER DA, et al.Type 2 diabetes and risk of hospital admission or death for chronic liver diseases[J].J Hepatol, 2016, 64 (6) :1358-1364. [18]SHANES JG, MINADEO KN, MORET A, et al.Statin therapy in heart Pailure:Prognostic effects and potential mechanisms[J].Am Heart J, 2007, 154 (4) :617-623. [19]STONE GW, ELLIS SG, COLOMBO A, et al.Effect of prolonged thienopyridine use after drug-eluting stent implantation (from the TAXUS landmark trials data) [J].Am J Cardiol, 2008, 102 (8) :1017-1022. [20]YI C, SONG Z, WAN M, et al.Statins intake and risk of liver cancer:A dose-response meta analysis of prospective cohort studies[J].Medicine (Baltimore) , 2017, 96 (27) :e7435. [21]DENG JL, ZHANG R, TANG J, et al.Research progress on the anti-tumor effects of statins[J].Chin J Clin Pharmacol T-her, 2017, 22 (1) :92-99. (in Chinese) 邓俊丽, 张蕊, 唐洁, 等.他汀类药物抗肿瘤作用的研究进展[J].中国临床药理学与治疗学, 2017, 22 (1) :92-99. [22]CAO Z, HUA FM, BELLOVIN DI, et al.MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-Co A reductase[J].Cancer Res, 2011, 71 (6) :2286-2297. [23]SINGH S, SINGH PP, SINGH AG, et al.Statins are associated with a reduced risk of hepatocellular cancer:A systematic review and metaanalysis[J].Gastroenterology, 2013, 144 (2) :323-332. [24]HSIANG JC, WONG GL, TSE YK, et al.Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population:A propensity score landmark analysis[J].J Hepatol, 2015, 63 (5) :1190-1197. [25]McGLYNN KA, DIVINE GW, SAHASRABUDDHE VV, et al.Statin use and risk of hepatocellular carcinoma in a U.S.population[J].Cancer Epidemiol, 2014, 38 (5) :523-527. -
本文二维码
计量
- 文章访问数: 1027
- HTML全文浏览量: 10
- PDF下载量: 296
- 被引次数: 0
下载:
